Literature DB >> 34669536

Cholangiocarcinoma: new perspectives for new horizons.

Margherita Rimini1, Marco Puzzoni2, Federica Pedica3, Nicola Silvestris4,5, Lorenzo Fornaro6, Giuseppe Aprile7, Eleonora Loi8, Oronzo Brunetti4, Caterina Vivaldi6, Francesca Simionato7, Patrizia Zavattari8, Mario Scartozzi2, Valentina Burgio9, Francesca Ratti10, Luca Aldrighetti10, Stefano Cascinu9, Andrea Casadei-Gardini9.   

Abstract

INTRODUCTION: Biliary tract cancer represents a heterogeneous group of malignancies characterized by dismal prognosis and scarce therapeutic options. AREA COVERED: In the last years, a growing interest in BTC pathology has emerged, thus highlighting a significant heterogeneity of the pathways underlying the carcinogenesis process, from both a molecular and genomic point of view. A better understanding of these differences is mandatory to deepen the behavior of this complex disease, as well as to identify new targetable target mutations, with the aim to improve the survival outcomes. The authors decided to provide a comprehensive overview of the recent highlights on BTCs, with a special focus on the genetic, epigenetic and molecular alterations, which may have an interesting clinical application in the next future. EXPERT OPINION: In the last years, the efforts resulted from international collaborations have led to the identification of new promising targets for precision medicine approaches in the BTC setting. Further investigations and prospective trials are needed, but the hope is that these new knowledge in cooperation with the new technologies and procedures, including bio-molecular and genomic analysis as well radiomic studies, will enrich the therapeutic armamentarium thus improving the survival outcomes in a such lethal and complex disease.

Entities:  

Keywords:  Cholangiocarcinoma; genomic analysis; immunotherapy; precision medicine

Mesh:

Year:  2021        PMID: 34669536     DOI: 10.1080/17474124.2021.1991313

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  1 in total

1.  Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.

Authors:  Margherita Rimini; Valentina Burgio; Lorenzo Antonuzzo; Lorenza Rimassa; Ester Oneda; Daniele Lavacchi; Nicola Personeni; Francesca Ratti; Federica Pedica; Angelo Della Corte; Mara Persano; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Target Oncol       Date:  2022-09-17       Impact factor: 4.864

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.